{"id":"lenacapavir-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4802249","moleculeType":"Small molecule","molecularWeight":"990.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenacapavir binds to the HIV capsid protein and stabilizes the viral capsid structure, preventing the release of viral RNA and reverse transcriptase into the host cell cytoplasm. This novel mechanism of action targets a distinct step in the HIV replication cycle compared to traditional antiretrovirals, potentially offering activity against drug-resistant strains and a long-acting profile suitable for infrequent dosing.","oneSentence":"Lenacapavir is a first-in-class HIV capsid inhibitor that prevents the uncoating of HIV viral particles, blocking early steps of viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:28.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced adults with multidrug-resistant virus"}]},"trialDetails":[{"nctId":"NCT06819176","phase":"PHASE1","title":"Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-20","conditions":"Human Immunodeficiency Virus","enrollment":50},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT07047716","phase":"PHASE3","title":"Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-07-22","conditions":"HIV Pre-exposure Prophylaxis","enrollment":350},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT07218211","phase":"PHASE4","title":"Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-13","conditions":"HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program","enrollment":100},{"nctId":"NCT06657885","phase":"PHASE2","title":"CAbotégravir LENacapavir DUal Long Acting","status":"WITHDRAWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2025-01-15","conditions":"HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment, CABOTEGRAVIR","enrollment":""},{"nctId":"NCT07335289","phase":"NA","title":"PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-02","conditions":"HIV Pre-exposure Prophylaxis Use","enrollment":400},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT06749054","phase":"PHASE2","title":"Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-03-26","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT06970223","phase":"PHASE1","title":"A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-04-22","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT06101329","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-11-17","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":253},{"nctId":"NCT06513312","phase":"PHASE2","title":"Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-07","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":268},{"nctId":"NCT04994509","phase":"PHASE3","title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-08-30","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":5368},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT06799338","phase":"","title":"Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-03-03","conditions":"HIV I Infection","enrollment":80},{"nctId":"NCT04811040","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-04-08","conditions":"HIV-1 Infection","enrollment":32},{"nctId":"NCT04143594","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-11-22","conditions":"HIV-1-infection","enrollment":183}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GS-6207","Yeztugo®","Sunlenca®","YEZTUGO®"],"phase":"phase_3","status":"active","brandName":"Lenacapavir Injection","genericName":"Lenacapavir Injection","companyName":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","companyId":"centre-de-recherches-et-d-etude-sur-la-pathologie-tropicale-et-le-sida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenacapavir is a first-in-class HIV capsid inhibitor that prevents the uncoating of HIV viral particles, blocking early steps of viral replication. Used for HIV-1 infection in treatment-experienced adults with multidrug-resistant virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}